摘要:
A process for the preparation of &agr;,&bgr;-unsaturated alcohols of general formula (I), wherein R means an alkyl group of 1-4 carbon atoms, or benzoyloxy group optionally substituted with a phenyl group; R1 means a hydrogen atom or an alkyl group of 1-4 carbon atoms, R2 means a hydrogen atom or an alkyl group of 1-4 carbon atoms; R3 means an alkyl group of 1-6 carbon atoms optionally substituted by phenyl group or cycloalkyl group of 5-7 carbon atoms; or a phenoxy group optionally substituted by a halogen atom, or a cycloalkyl group of 5-7 carbon atoms; R4 means a hydrogen atom or a halogen atom whereby at &agr;,&bgr;-unsaturated ketones of general formula (II) wherein the meanings of R, R1, R2, R3, and R4 are as given above—is diastereoselectively reduced with a borohydride type compound in an aprotic solvent, in the presence of an inorganic substance dissolublein the reaction mixture and having particle size from 0.01 micrometer to 10000 micrometer and optionally from the resulting mixture of epimeric &agr;,&bgr;-unsaturated alcohols of general formula (I) and (III) meanings of R, R1, R2, R3, and R4 are as given above—the &agr;,&bgr;-unsaturated alcohol of general formula (I) is separated by methods known.
摘要:
The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.
摘要翻译:本发明涉及通式(I)的腺苷A 3 N 3受体配体,其中优选的是拮抗剂,以及它们的盐,溶剂化物和异构体,以及含有它们的药物组合物 的通式(I)化合物及其盐,溶剂合物和异构体制备通式(I)化合物及其盐,溶剂合物和异构体,此外还涉及一般的新的中间体 式(II)及其制备方法。
摘要:
The present invention relates to adenosine A3 receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.
摘要:
The present invention relates to adenosine A3? receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and theirs salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.